Literature DB >> 20008944

The development of the Feighner criteria: a historical perspective.

Kenneth S Kendler1, Rodrigo A Muñoz, George Murphy.   

Abstract

This essay outlines the historical context in which the Feighner criteria emerged; reconstructs, as far as possible, the process by which the criteria were developed; and traces the influence the criteria had on subsequent developments in American psychiatry. In the 1950s, when American psychiatry under psychoanalytic dominance had little interest in psychiatric diagnosis, Edwin Gildea recruited to the Department of Psychiatry at Washington University faculty who advocated a medical model for psychiatry in which diagnosis had a central role. In 1967, at the urging of the then-resident John Feighner, a discussion group led by Eli Robins and including Sam Guze, George Winokur, Robert Woodruff, and Rod Muñoz began meeting with the initial goal of writing a review of prior key contributions to psychiatric diagnosis. In their meetings over the next year, the task soon shifted to the development of a set of new diagnostic criteria. For three diagnoses, major depression, antisocial personality disorder, and alcoholism, the authors could identify the original criteria from which this group worked and the rationale for many of the changes they introduced. Published in 1972, the Feighner criteria were soon widely cited and used in research, and they formed the basis for the development of the Research Diagnostic Criteria, which in turn were central to the development of DSM-III. The team that developed the Feighner criteria made three key contributions to psychiatry: the systematic use of operationalized diagnostic criteria; the reintroduction of an emphasis on illness course and outcome; and an emphasis on the need, whenever possible, to base diagnostic criteria on empirical evidence.

Entities:  

Mesh:

Year:  2009        PMID: 20008944     DOI: 10.1176/appi.ajp.2009.09081155

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  21 in total

1.  The structure of genetic and environmental risk factors for fears and phobias.

Authors:  E K Loken; J M Hettema; S H Aggen; K S Kendler
Journal:  Psychol Med       Date:  2014-01-02       Impact factor: 7.723

2.  Evidence for multiple genetic factors underlying DSM-IV criteria for major depression.

Authors:  Kenneth S Kendler; Steven H Aggen; Michael C Neale
Journal:  JAMA Psychiatry       Date:  2013-06       Impact factor: 21.596

3.  Taking an RDoC lens to the study of panic disorder: A commentary on Hamm et al. and other thoughts on RDoC.

Authors:  Stewart A Shankman; Andrea C Katz; Scott A Langenecker
Journal:  Psychophysiology       Date:  2016-03       Impact factor: 4.016

4.  [On the differential diagnostics of depersonalization experiences].

Authors:  M Bürgy
Journal:  Nervenarzt       Date:  2012-01       Impact factor: 1.214

5.  Incremental advances in psychiatric molecular genetics and nosology.

Authors:  Kenneth S Kendler
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

Review 6.  Circuit-Targeted Neuromodulation for Anhedonia.

Authors:  Shan H Siddiqi; Nichola Haddad; Michael D Fox
Journal:  Curr Top Behav Neurosci       Date:  2022

7.  Nosology of behavioral addictions: Intersections with philosophy of psychiatry •.

Authors:  Dan J Stein; Christine Lochner
Journal:  J Behav Addict       Date:  2022-07-13       Impact factor: 7.772

8.  Deconstructing major depression: a validation study of the DSM-IV symptomatic criteria.

Authors:  V Lux; K S Kendler
Journal:  Psychol Med       Date:  2010-01-11       Impact factor: 7.723

9.  When does depression become a disorder? Using recurrence rates to evaluate the validity of proposed changes in major depression diagnostic thresholds.

Authors:  Jerome C Wakefield; Mark F Schmitz
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

Review 10.  Data-driven subtypes of major depressive disorder: a systematic review.

Authors:  Hanna M van Loo; Peter de Jonge; Jan-Willem Romeijn; Ronald C Kessler; Robert A Schoevers
Journal:  BMC Med       Date:  2012-12-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.